DIA/FDA Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

亮点与特色

Need Approval in Order to Attend?

Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.

Learn about the latest advancements, regulatory updates, and emerging trends in oligonucleotide therapies directly from leading industry experts and global regulators
Our three tracks (Clinical, Nonclinical, and CMC) will comprehensively cover a wide range of aspects of oligonucleotide therapeutics—from development to regulatory collaboration—and provide practical insights into current challenges and successful strategies for overcoming hurdles in clinical use, safety assessments, and CMC
This conference offers a networking opportunity to engage with peers, innovators, and regulators in sessions designed to foster meaningful collaboration and knowledge exchange